ABSTRACT
Co-existence of haemorrhagic and thrombotic events is well recognised, for example following the consumptive coagulopathy of disseminated intravascular coagulation (DIC). In the management of chronic haemorrhagic conditions however, concern regarding possible deep venous thromboses (DVT) and pulmonary emboli (PE) may not be paramount.
Hereditary haemorrhagic telangiectasia (HHT, also known as Osler-Weber-Rendu syndrome) leads to chronic haemorrhage due to primary vascular wall pathology. Affecting at least 1 in 5,000-8,000 in Europe 1, 2 , HHT is classically recognised by nose bleeds, characteristic mucocutaneous telangiectasia on the lips, oral mucosa and fingertips, and anaemia secondary to chronic haemorrhage from telangiectasia in the nose and gastrointestinal tract. HHT also leads to the development of large arteriovenous malformations (AVMs) in pulmonary, cerebral and hepatic circulations 3, 4 . Concurrent coagulation defects are only rarely described [5] [6] [7] [8] [9] [10] . In contrast, all patients have abnormal vascular structures at the sites of haemorrhage.
HHT telangiectasia display focal dilatations, asymmetric wall development, and turbulent blood flow due to microscopic arteriovenous communications 11, 12 We hypothesised that HHT might result in disturbances to the tightly regulated dynamics involved in regulation of coagulation and fibrinolysis at the endothelial cell surface, and examined whether there were any HHT-specific factors that may exacerbate or modify conventional risk factors for thrombosis 22, 23 .
METHODS
All studies were ethically approved by the Hammersmith, Queen Charlotte's, Chelsea, and Acton Hospital Research Ethics Committee (LREC 00/5792, LREC 00/5908 and LREC 02/6289).
Study design and patient populations
The study was performed in two phases: A pilot study was first performed in otherwise healthy HHT patients and age/sex matched controls in order to identify processes perturbed as a consequence of HHT itself. In the second phase, a study in the full HHT population was performed to determine whether any perturbations were likely to influence thrombotic risk.
The full study population were the 309 individuals with definite HHT 24 , reviewed in our individuals from this population, selected because they were otherwise healthy, and had never had a suspected or proven deep venous thrombosis or pulmonary embolus. Non-HHT controls for the pilot study were recruited from spouses or hospital staff. 
HHT assessment

Pilot study
A pilot study comparing plasma proteins from HHT-affected individuals to age and sexmatched non-HHT controls was designed with the power to detect a difference of 0.6 standard deviation for tests at the 5% significance level (two-tailed). Strict exclusion criteria to reduce confounding influences were current or previous thromboses, intercurrent ill health/intervention, and hormonal or prothrombotic treatment in the previous year. 
RESULTS
Pilot study
Plasma levels of VWF:Ag were age-related ( Figure 1A ) and significantly higher in the HHT/noVTE individuals than in age-matched non-HHT controls ( Figure 1B ). Plasma levels of FVIII:Ag were also age-related ( Figure 1C ) and significantly higher in HHT/noVTE individuals, compared to age-matched non-HHT controls ( Figure 1D ). Plasma concentration of VWF:Ag and FVIII:Ag were highly correlated in both groups ( Figure 1E ).
Possible explanations were explored. There was no significant difference in the acute phase proteins CRP and fibrinogen between the groups (data not shown), and none of the HHT/noVTE group had abnormal liver function tests, or evidence of overt DIC ( Figure 1F ).
There was no difference between the groups in the proportion of blood group O individuals (who have significantly lower plasma concentrations of VWF and hence FVIII:Ag 34 ; 2 = 1.975, p=0.16), nor in PAI-1, soluble thrombomodulin or soluble P-selectin, the other proteins which had been measured in the pilot study (data not shown).
FVIII:Ag in general HHT population
In the full study, service laboratory FVIII:Ag was measured at least 4 months from any illhealth/intervention, and at least 10 months from any VTE. In this selected healthy HHT Factors that might contribute to elevated FVIII:Ag levels in HHT were explored as they could confound analyses of FVIII:Ag contribution to thrombotic risk in HHT. In univariate analyses, log-transformed FVIII:Ag measured ≥10 months from VTE was significantly correlated with age, fibrinogen levels, presence of pulmonary AVMs, and use of oral iron supplements (a marker of HHT-related haemorrhage), but not with Hb or CRP ( Table 1) .
Pulmonary hypertension, particularly thromboembolic pulmonary hypertension, is associated with elevated FVIII levels (ref) . Pulmonary hypertension may occur in HHT (ref tremb). In our overall cohort, pulmonary hypertension was rare (Figure 2 ), only one of the 78 patients with FVIII measurements had significant pulmonary hypertension (associated with FVIII:Ag of 1.77u/ml, the median value for population), and there was no correlation between PAP and FVIII:Ag (Table 1) . (Table 2) . Again, there was no association with CRP, and once adjusted for age, neither fibrinogen nor oral iron use correlated with log-transformed FVIII:Ag (data not shown). The best model suggested however, that the unexpected association of pulmonary AVM with the level of FVIII:Ag might be independent of age ( Table 2) . 
FVIII:Ag and APTT
High FVIII:coagulant activity is associated with shortening of the activated partial thromboplastin time (APTT) 37 , reflecting the proximal position of FVIII in the cascade reactions measured by the APTT ( Figure 3A) . To validate the FVIII:Ag measurements used for this study, correlations between FVIII:Ag and APTT were performed. In both pilot ( Figure 3B ) and full ( Figure 3C ) studies, FVIII:Ag levels inversely correlated with the APTT.
The inverse correlation with APTT was maintained following log transformation of FVIII:Ag ( Figure 3D ).
Venous thromboemboli in full HHT population
To address whether FVIII:Ag influenced prothrombotic risk, association with VTE was examined. In the full study population, 20/309 (6.5%) individuals from 19 different HHT families gave a history of venous thromboembolic event either prior to review (n=16, including three with more than one event), or in the period of follow-up (n=4). Ages at the time of VTE ranged from 28-72 (Q 1 38, Q 2 50, Q 3 6) yr. 7/20 HHT/VTE patients had needed transfusions reflecting the high proportion of the overall HHT population with evidence of significant haemorrhage (Table 1) . Fourteen had pulmonary AVMs.
Clinical risk factors for thrombosis were present in 13/20 HHT/VTE patients and included commencement on oestrogens in the preceding month (n=2), protein S deficiency (n=1; the sole HHT/VTE individual with detected abnormalities in protein C, protein S and antithrombin III), and recent long distance flight (n=1). Nine HHT patients developed VTE while hospital inpatients; five while recovering from a brain abscess secondary to pulmonary AVMs, two with liver failure or recent hepatic embolisation, and two with indwelling venous catheters for other conditions.
Univariate analyses did not suggest that transfusion need or other markers of HHT-related haemorrhage were protective against VTE (Table 3 ). The majority of individuals had pulmonary AVMs but there was no difference in the severity of pulmonary AVMs as quantified by right-to-left shunt, or oxygen saturation, between those experiencing and not experiencing thrombosis (Table 3 ). The univariate analyses did suggest that older individuals with HHT were at higher risk of VTE, as in the general population 22, 23 (Table 3) . months from VTE with VTE risk (Table 4 ). The odds ratio of experiencing DVT was 2.41 (95% confidence intervals 1.25, 4.61) for a unit increase in baseline log transformed FVIII:Ag. Age made no additional contribution once adjusted for FVIII:Ag (Table 4) . 
DISCUSSION
This study reports an elevation of FVIII:Ag levels in HHT, an elevation of probable functional significance for long term thrombotic risk. The findings imply that the possibility of thrombotic events cannot be ignored in HHT patients, even when transfusion-dependent.
A similar concern has been raised for individuals with other haemorrhagic disorders including haemophilia 39 .
The strengths of this study include the large numbers examined in a condition where many clinicians see only isolated cases. In addition, the study design attempted to minimise bias from independent factors leading to high FVIII levels, and included assessments of pulmonary artery pressure to exclude pulmonary hypertension as a cause for elevated FVIII:Ag in this population with predominantly normal pulmonary artery pressures. One potential weakness was the retrospective nature of the VTE assessments in most individuals.
A further important factor was the high frequency of pulmonary AVMs in our population.
The population was screened using a highly sensitive screening tool (thoracic CT scan with dedicated protocol). In a recent CT-and angiography-verified study 40 , pulmonary AVMs affected at least 48.6% of a French HHT population compared to 5-15% in less well-screened populations 3, 36 ). Nevertheless, a pulmonary AVM bias was undoubtedly present in our population.
Before assessing whether elevated FVIII:Ag might be associated with VTE risk, we explored mechanisms that may contribute to elevation of FVIII:Ag levels in the HHT population.
There was no evidence for involvement of DIC, impaired fibrinolysis or platelet activation.
CRP measurements confirmed that our study design had generally excluded individuals with Furthermore, in the HHT study population, we demonstrated that a single baseline service laboratory measurement of plasma FVIII:Ag was independently associated with the risk of VTE approximately 1-11 years from the measurement. Again, these findings are in-keeping with evidence emerging from the general population that high FVIII levels are associated with first and recurrent episodes of venous thrombosis 31, 42 . Intriguingly, in the best model of our data, age made no additional contribution to VTE risk. We speculate that age-dependent increases in FVIII as seen in our study, and in the general population 41 , may be a major contributor to the increased risk of VTE with age 22, 23 .
FVIII:Ag levels were likely to be only one of multiple factors contributing to the thrombotic profile of individuals with HHT. Where the diagnosis of underlying HHT had been recognised, it was generally considered a relative contraindication to prophylactic and subsequent therapeutic anticoagulation of individual patients. As expected, inheritance of HHT did not protect against chance co-inheritance of independent prothrombotic genetic polymorphisms which occurred at frequencies which corresponded to those reported for a control UK population. There was however, a significant excess of FV Leiden genotype in HHT patients who experienced thromboses, as in the general population for whom a 2.7 fold increase in VTE risk has been cited 27 . FV Leiden heterozygosity appeared to be associated particularly with VTE in the period following a pulmonary AVM-induced brain abscess, a condition resulting in an acute phase response, neurosurgical intervention, and prolonged intravenous antibiotics. HHT telangiectatic lesions and their progressive development limit the efficacy of endoscopic, embolisation and surgical treatments for nasal and gastrointestinal haemorrhage 43 . To limit blood loss, therapeutic manipulation of coagulation and fibrinolytic pathways is often employed using conjugated oestrogens 44 , or prothrombotic agents such as tranexamic acid 45 and aminocaproic acid 46 .
The data presented here lead us to conclude that individuals with HHT may be at a higher risk 
